manifest: ruxolitinib plus pelabresib for jak-inhibitor naïve myelofibrosis
Published 3 years ago • 156 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
2:41
benefits of pelabresib with ruxolitinib for treatment naïve myelofibrosis
-
1:00
the promising role of pelabresib in the treatment of mf
-
2:44
trial in progress: anti-slamf7 elotuzumab in jak2-mutated myelofibrosis
-
2:36
the impact of early intervention in myelofibrosis
-
4:35
the role of jak2 vaf testing in risk assessment and disease monitoring in mpns
-
2:10
manifest update: pelabresib clinical and pathological investigations
-
1:30
insights into the manifest-2 study
-
1:55
the promise of pelabresib in mf and insights into the manifest-2 study
-
2:21
recent updates on pelabresib for myelofibrosis
-
1:49
results from manifest phase ii study of pelabresib for anemia associated with myelofibrosis
-
3:55
manifest: pelabresib updates
-
1:58
current research into jak inhibitors - specifially ruxolitinib, pacritinib, and momelotinib
-
4:26
bet inhibition as a novel targeted therapy for myelofibrosis
-
2:12
ruxopeg: a promising novel combination for mpn-associated myelofibrosis
-
5:00
treatment options for ruxolitinib intolerance or resistance in myelofibrosis
-
0:09
yt post